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CRC Department of Cancer Genetics, Paterson Institute for Cancer Research, Christie Hospital, Wilmslow Road, Manchester M20 9BX, UK
Summary Twenty-three cases of ductal carcinoma in situ (DCIS), ten of which had an associated invasive component, were studied for loss
of heterozygosity (LOH) of microsatellite markers on chromosome 9p and the results compared with a panel of 20 invasive breast
carcinomas. In addition to the gene encoding p16, chromosome 9p is also thought to contain other putative tumour-suppressor genes. If the
three panels of breast tumours showed LOH of markers in this region this would suggest that such putative genes were important in breast
carcinogenesis. By studying both preinvasive and invasive breast tumours, it should also be possible to gain further information about the
relationship between lesions of a different stage and to determine whether DCIS is indeed a precursor of invasive ductal carcinoma. Levels of
LOH were low in the invasive-only set of tumours. Surprisingly, considerably higher levels of loss were observed in the tumours with an in situ
component. Also, much heterogeneity was observed between different DCIS ducts or invasive tumour and DCIS from the same case.
Keywords: ductal carcinoma in situ; microdissection; loss of heterozygosity; heterogeneity
Breast cancer remains one of the most common cancers in the
Western world and overall it is estimated that approximately 1 in
10 women will develop this disease at some point in her life
(Stratton and Wooster, 1996). Therefore, identification ofenviron-
mental, biochemical and genetic factors that may be important in
the aetiology and progression ofthis disease is essential in order to
improve prevention, diagnosis and therapy. Conventionally, inva-
sive cancer is regarded as developing through a series of events
morphologically recognized as hyperplasia, atypical hyperplasia
and in situ carcinoma, although for breast cancer this pathway of
intermediate stages may be discontinuous and is certainly not
universal. Although a variety ofprecursors ofmalignancy may be
present in tissue surrounding invasive carcinoma, it is not
uncommon for a cancer to be found in isolation, with no evidence
of a non-infiltrating component in the area and no hint as to the
nature of the progenitors of the disease. A close relationship
between the preinvasive lesion ductal carcinoma in situ (DCIS)
and invasive breast carcinoma has been postulated, as DCIS is
frequently present in tissues adjacent to breast cancer (Ottesen
et al, 1992; Schwartz et al, 1992). Furthermore, invasive breast
cancers in women with DCIS generally occurin the same region of
the same breast in which DCIS was originally identified (Lagios,
1993). By studying specific genetic alterations present in both
preinvasive and invasive breast cancer, it was hoped to learn more
about the relationship between these different stages.
In primary human breast tumours, loss ofheterozygosity (LOH)
represents the most frequent type ofgenetic alteration (Callahan et
al, 1993). The assumption that LOH unmasks recessive alleles
involved in tumorigenesis enables LOH analysis to be carried out
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on tumour DNA vs normal DNA, to determine the possible loca-
tion oftumour-suppressor genes.
The chromosome region 9p21-p22 has attracted much research
interest over recent years because ofthe identification, in 1994, of a
new genep16 (also known asMTSJ, formultiple tumour-suppressor
1, INK4a and CDKN2, forinhibitorofcyclin-dependent kinase). The
discovery thatthegeneis homozygously deletedin alargenumberof
human tumour cell lines (Kamb et al, 1994; Nobori et al, 1994)
suggested thatp16 was behaving as a tumour-suppressor gene. The
p16 protein had already been described as an inhibitor of cyclin-
dependent kinases, which are themselves key regulators of the cell
division cycle (Serrano et al, 1993). Loss ofsuch an inhibitor would
probably result in unregulated proliferation, thus reinforcing the
support for p16 as a tumour suppressor. More recently, the avail-
ability ofthepl6-/-mouse (Serrano etal, 1996) andtheobservation
that some familial melanoma families harbour germnlne point muta-
tions or deletions within thep16 gene (Hussussian et al, 1994; Gruis
et al, 1995) have provided further evidence that p16 is a tumour-
suppressorgene. A second gene in this region,p15, also behaves as a
tumour suppressor (Sonadaet al, 1995).
Regions of chromosome 9p have been found to be frequently
rearranged or deleted in a range of primary tumours and often
show LOH of genetic markers. There is evidence for a bladder
cancer suppressor locus on chromosome 9p2l (Ruppert et al,
1993; Devlin et al, 1994; Orlow et al, 1994) with highest levels of
loss at the IFNA gene cluster. Similar studies on other human
tumours show significant LOH of the same region encompassing
IFNA, including lung cancer (Mead et al, 1994; Merlo et al, 1994),
glioma (Ichimura et al, 1994), renal cell carcinoma (Cairns et al,
1995) and oesophageal cancer (Tarmin et al, 1994). Some ofthese
studies also describe high levels ofloss both proximal anddistal to
IFNA, which are probably not targetingpl6.
This study describes the assessment of LOH of microsatellite
markers spanning chromosome 9p, to determine the location of
putative tumour-suppressor genes involved in breast cancer.
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Table 1 Histology of tumours
Case number Histological classification Nuclear grade
DCIS
2652 Comedo, solid Intermediate
2969 Comedo, cancerization of lobules Intermediate
4419 Comedo, cancerization of lobules, microinvasion High
6050 Solid, micropapillary. Duct ectasia, tiny focus of invasion High
2238 Comedo, cribriform. Lobular cancerization. Small focus of invasion High
2239 Comedo, solid. Lobular cancerization High
2242 Comedo, cribriform. Florid fibrocystic disease High
3812 Comedo Intermediate/low
601 Comedo. Occasional microinvasion High
6092 Comedo. Small foci of invasion High
1960 Solid. Fibrocystic change. Early microinvasion High
2659 Comedo. Some stromal invasion High
4842 Solid. Cancerization of lobules Low
DCIS + invasive Grade of DCISJinv
3144 Micropapillary. Invasive carcinoma. Fibrocystic disease Intermediate/grade II
6457 Comedo, micropapillary. Invasive High
452 Micropapillary. Infiltrating ductal carcinoma High/grade II
3041 Cribriform, solid. Tubular carcinoma Intermediate/grade
4410 Comedo. Infiltrating ductal carcinoma Intermediate/grade III
6256 Cribriform. Infiltrating ductal carcinoma Intermediate/grade II
6384 Comedo. Infiltrating ductal carcinoma High/grade II
613 Cribriform. Invasive carcinoma Low
2753 Cribriform, solid. Infiltrating ductal carcinoma Low-intermediate/Il
2931 Micropapillary. Infiltrating ductal carcinoma High/grade IlIl
Invasive cancers graded according to WHO guidelines. DCIS characterized using criteria based on nuclear grade.
MATERIALS AND METHODS
Tumour samples
Formalin-fixed, paraffin-embedded tumour tissue from 23 cases
containing DCIS was obtained from Christie Hospital,
Manchester, UK. Details ofthe histopathology and grade of these
cases are given in Table 1. High molecular weight DNA had previ-
ously been prepared from frozen tumour material from a further 20
invasive breast cancer cases, for which there was also available the
corresponding constitutional DNA, prepared from blood.
Microdissection and DNA extraction
Areas of normal tissue, ducts containing DCIS and, where present,
invasive carcinoma were microdissected from a single dewaxed
20-im paraffin section, with reference to an adjacent haematoxylin-
and eosin-stained section. Care was taken not to contaminate
tumour cells with normal cells. DNA was extracted by standard
methods (Sambrook et al, 1989). When this supply of DNA had
been used, the same ducts and regions of tissue that had originally
been taken were subsequently microdissected from the equivalent
area on serial sections, to enable experiments to be repeated.
PCR amplification
Primary PCRs were carried out in a volume of 20 pl, containing
340 gM each dNTP (Promega), 6 ng pl-l each of forward and
reverse primer, 0.5-2 units Thermoprime plus DNA polymerase
(Advanced Biotechnologies) and either 2-5 gl of DNA extracted
from the microdissected tissue or 1 p1 ofblood-tumour DNA from
the invasive breast cancer cases. Reactions were subjected to
cycling conditions specific foreach primerpair, with 25-50 cycles
of denaturation at 94°C (typically 37 cycles for invasive tumour
DNA and 43 cycles for DNA from microdissected material),
annealing at temperatures of55-620C and extension at 72°C, each
for 1 min. All polymerase chain reaction (PCR) programmes
incorporated a denaturation step of94°C for 4 min before cycling,
with a final extension step of72°C for 10 min after cycling.
An aliquot of 1 gl ofproduct from the primary PCR was seeded
into a 20-,ul secondary PCR containing only one of the original
primers, which had been end-labelled with [y32P]ATP using T4
polynucleotide kinase (200 ng of primer DNA and 1 gCi of ATP
per reaction). The second round PCR programme consisted ofjust
three cycles of 1 min at 940C, 1 min at 55-62'C and 1 min at
72°C, followed by 2 min at 94°C, 5 min at 55-620C and finally
10 min at 72'C.
Oligonucleotide primers
Oligonucleotide primers described in Kwiatkowski and Diaz
(1992), Weissenbach et al (1992), Wilkie et al (1992) and Gyapay
et al (1994), were used to amplify microsatellite markers of the
(CA)n repeat type. Relative positions of these markers are shown
in Figure 1.
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Figure 1 Human chromosome 9p, showing microsatellite markers.
Consensus intermarker distances in cM, sex-averaged, taken from
Kwiatkowski et al (1993) and Dib et al (1996). Markers originally identified by
AFM code have been given their current D9S code (brackets)
Detection of LOH
Radioactive PCR products were run on adenaturing 6% polyacryl-
amide gel at 75 W for 2-4 h. Dried gels were exposed to medical
X-ray film that was developed by being placed in Kodak D19
developer and Ilford Hypam fixer followed by thorough washing
with water. Foreach case the autoradiogram was studied and DNA
from both normal and tumour material was assessed for differ-
ences in the intensity ofthe alleles between the two. Complete loss
or reduction in intensity of over 40% (Hoggard et al, 1995) of one
allele in the tumour relative to normal was considered to be LOH.
For those cases that appeared to show loss of a particular marker,
primary and secondary PCRs were repeated to confirm the result.
To ensure that results were not caused by PCR artefacts, this was
done using both the original DNA extract (when available) and
DNA prepared from material freshly microdissected from the
same duct on an adjacent serial section. A representative number
of cases showing retention were also repeated, to confirm repro-
ducibility ofthis technique.
RESULTS
The results ofthe LOH study for each ofthe three separate tumour
sets, invasive-only tumour, DCIS-only and invasive tumour with a
DCIS component, are represented in Table 2. In addition, the
percentage of informative ducts showing LOH was recorded for
each marker (% loss).
Invasive cases
As can be seen in Table 2a, eight of the twenty infiltrating carci-
nomas show loss of at least one marker on chromosome 9p. Of
these cases, five show loss of more than one marker (129, 219,
330, 343 and 353), with regions of retention in between. This
suggests the presence of interstitial deletions, rather than the
complete loss ofthe short arm.
Only two tumours (330 and 343) show loss of one or both
markers that flank p16 (IFNA and D9S171). Case 330 demon-
strates allelic imbalance at a number of markers across chromo-
some 9p, including a reduction in intensity of the lower allele at
D9S285 (Figure 2A) and D9S1846/AFMb325zh9 (Figure 2B) and
complete loss of the upper allele at markers IFNA and D9S171
(Figure 2C and D). The adjacent marker D9S1679/AFM337tb5
shows areduction in intensity ofthe upper allele and there is reten-
tion ofthe more proximal marker D9S104 (Figure 2E and F). The
fact that there is clear loss of the markers flanking pl6 indicates
that the DNA template is relatively free from contaminating
normal cells and that all cells may have undergone a targeted loss
of p16. However, the presence of allelic imbalance rather than
clear loss at other markers might suggest that only a proportion of
cells carry a deletion of these particular markers. This could be
explained if loss of the p16 region was a relatively early event
in the tumour's development, followed by the divergence of
subclones, some of which undergo loss of other markers on
chromosome 9p at a later stage.
Levels of loss at most other markers are also relatively low and
may be explained by a background level of random genetic loss,
which is generally considered to be approximately 15%. However,
markers D9S1679 and D9S165 are lost in approximately 20% of
informative cases and marker D9S285 is lost in 33% of cases,
which may indicate the presence of putative tumour-suppressor
genes in these regions.
DCIS cases
In contrast to the results obtained for the invasive breast tumours,
levels of LOH in the DCIS cases were significantly higher (Table
2b). Twelve of the thirteen cases studied showed loss of at least
one marker on chromosome 9p. Each ofthe four subtypes ofDCIS
studied: comedo, cribriform, micropapillary and solid, were
affected by loss ofat least one marker, although the cases generally
showing most extensive regions of loss, affecting multiple
markers, were of the comedo or cribriform subtype. Case 2659
demonstrated loss ofall informative markers that weretested, indi-
cating loss ofthe complete short arm. A number ofcases appeared
to have undergone interstitial deletions, with retention of markers
adjacent to regions ofloss.
As the microdissection technique enabled precise removal of
distinct ducts from the same tumour, it was possible to study the
genetic alterations present in several separate ducts from the same
case. It was thought that the comparison of such results would
provide information on the clonality of these preinvasive lesions,
for example the finding ofthe same genetic alteration in different
ducts would support the idea that both ducts had developed from a
common progenitor. However, this proved not to be the case and,
of the ducts tested, a distinct pattern of allelic loss was observed
in each.
Examples were found in which different ducts demonstrated
imbalance ofopposite alleles, suggesting that the ducts had under-
gone quite separate genetic alterations affecting different chromo-
somes. A number of comedo ducts from case 2238 were studied
(Figure 3) and, taking the IFNA marker as an example, these ducts
variously demonstrated retention of both alleles (C), loss of the
lower allele(C2) or loss ofthe upper allele (Cl and C4).
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Figure 2 Case 330 showing clear loss of the upper allele at the IFNA and D9S171 markers in the invasive DNA (I) compared with the normal DNA (N). Allelic
imbalance can be seen in the flanking markers (A), (B) and (E), with retention of both alleles at marker (F) D9S104
these high levels of loss may indicate the location of putative
tumour-suppressor genes.
N Cl* C* C, CA*
Figure 3 Several different comedo ducts taken from case 2238 show
evidence of having undergone distinct genetic alterations. Duct C5 shows
retention of both alleles of the IFNA marker. Duct C2 shows loss of the lower
allele in contrast to duct C4, which shows loss of the upper allele. Duct C,
shows allelic imbalance with a reduction in intensity of the upper allele.
*Cases showing LOH
Six ofthe thirteen DCIS cases studied demonstrated LOH of at
least one marker flanking p16 (IFNA or D9S171) that could
potentially have arisen as a result of targeted loss ofpil6 accom-
panied by loss of additional markers. The IFNA marker was lost
in 50% of ducts examined. High levels of loss comparable with
this were also found at markers both proximal and distal to pi6.
As had been observed in the invasive cases, markers D9S165 and
D9S285 were among those affected with the highest frequency,
being lost in > 40% of cases. However, D9S1846 and D9S1679,
like IFNA, were lost in 50% of cases, although the number of
ducts assessed was only relatively small in each case. Again,
DCIS cases with an invasive component
A number of markers spanning chromosome 9p were successfully
amplified from both comedo DCIS DNA (C) and infiltrating
ductal carcinomaDNA (I) from case4410. As the results in Table 2c
and Figure 4 show, concordance between these two components
was found in every case. These results suggest that, in this case at
least, the DCIS and the invasive tumours are intimately related, the
most likely explanation being that the DCIS was the precursor
lesion. However, a more complex pattern of genetic alterations is
observed in other cases, with the preinvasive and invasive compo-
nents not showing the same changes. For example case 6256
demonstrates retention of both alleles of the IFNA marker in the
cribriform DCIS but loss ofthe upper allele in the invasive compo-
nent, perhaps indicating that loss ofthis particular region is impor-
tant in the progression from in situ to invasive carcinoma (Figure 5).
A slightly more complex situation is shown in Figure 6. As had
been observed in the subgroup of tumours containing DCIS only,
when numerous ducts were microdissected from cases containing
both DCIS and carcinoma, retention of both alleles was found in
some ducts, with LOH in others. Also, as noted previously, losses
in different ducts may affect different alleles, reinforcing the idea
that DCIS shows considerable genetic heterogeneity.
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Figure 4 Case 4410 showing concordance between genetic alterations
observed in the comedo DCIS (C) and invasive components (I). LOH is
observed in both preinvasive and invasive tumour at every marker tested,
including (A), (B), (C) and (E), except marker (D) D9S104, which shows
retention in both C and
DISCUSSION
Despite the uncertainty regarding the relevance of losses flanking
pi6, the levels of loss at other markers on chromosome 9p, in the
DCIS and DCIS/invasive cases in particular, suggested the
possible location of other tumour-suppressor genes both proximal
and distal to pi6. D9S285 was lost at consistently high frequency
(> 30%) across the three tumour sets, as were markers D9S1679
and D9S165. Also, although levels ofloss in the invasive panel of
tumours were low, the markers D9S1788 and D9S162 were lost in
approximately 40% or more of cases in the remaining two groups
of tumours. Other studies looking at LOH of microsatellite
markers spanning chromosome 9p in various tumours have found
similar results, with many losses centred around the IFNA marker,
but also extending proximally and distally (Olopade et al, 1993;
Coleman et al, 1994; Neville et al, 1995).
One purpose of the study had been to attempt to gain more
information about the natural history of breast cancer and the
molecular changes accompanying progression. This study and
Figure 5 Possible genetic alterations accompanying progression. Case
6256 showing retention of both alleles of marker IFNA in the cribriform DCIS
(Cr) and loss of the upper allele (*) in the invasive component (I). This may
indicate that deletion of this region of chromosome 9p is important in the
progression to invasive ductal carcinoma
others (James et al, 1997) have confirmed that genetic changes
found in DCIS lesions are similar to those found in invasive breast
carcinoma. Furthermore, a recent paper has also described some
changes in morphologically normal tissue adjacent to breast
carcinomas (Deng et al, 1996).
One significant conclusion to be drawn from this work is that,
even at the preinvasive stage of DCIS, breast cancer is a hetero-
geneous disease in which the pathway of changes accompanying
progression is far from clear. Although the results indicated that
some DCIS lesions are likely to be the precursors of invasive
cancer, because both components showed identical allele loss for
particular markers, this is not true for all DCIS, some of which
have quite distinct genetic alterations to those of the invasive
component. Reports in the literature have described both situa-
tions. A study by Zhuang et al (1995) assessed allelic imbalance
of markers on chromosome 1q13 in microdissected in situ and
invasive human breast cancer. This provided evidence for a
tumour-suppressor gene in this region that may be important in
breast cancer development, and also indicated that invasive breast
cancer arises from in situ lesions. However, similar studies
looking at allelic imbalance have described intratumour hetero-
geneity with the probable existence of subpopulations of tumour
cells (Chen et al, 1992; Bonsing et al, 1993). An extension ofthis
has been noted in studies similar to this one, in which several
ducts from the same case were treated independently. In agree-
ment with the results described in this study, heterogeneity with
respect to allele loss was found in different neoplastic foci of in
situ cancer and in some cases allelic losses present in in situ
regions were not conserved in the progression to invasive tumour
(Munn et al, 1995; 1996; Fujii et al, 1996).
It remains surprising that the degree of loss observed in the
invasive-only set of tumours was so much less than that found in
the other two sets. It might be expected that because the DCIS
lesions show such a high level ofloss of markers on chromosome
9 that they may show a correspondingly high frequency ofloss of
other markers across the genome. However, this has been shown
not to be the case (Aldaz et al, 1995; Radford et al, 1995), with
allelotype studies on DCIS showing levels of loss less than those
found in invasive breast carcinomas. Although direct comparisons
between the three sets oftumours cannot be made and numbers are
small, the results of this study may suggest that this particular set
of invasive lesions is fundamentally different to those lesions that
have an intraductal component. A similar result has previously
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Figure 6 Both loss and retention of the same marker in different ducts from
the same case. (A) The comedo duct (C) from case 6457 shows retention of
the upper allele of marker D9S162 in contrast to the micropapillary duct (M),
which shows clear loss of this allele. Similarly, in case 2753 clear LOH is
seen in the cribriform duct (Cr), in contrast to the retention of both alleles
seen in the solid (5) duct. (B) This phenomenon is not confined to ducts of
different subtype, as different comedo ducts from case 6457 show different
results when the genotype of the IFNA marker is assessed. (C) A further level
of heterogeneity exists between individual ducts from the same case. Case
6457 demonstrates retention of both alleles at marker D9S104 in duct C4.
However, ducts ° and E show loss of opposite alleles, indicating that they
have undergone distinct genetic alterations affecting different chromosomes
been obtained from immunohistochemical studies of the protein
encoded by the c-erbB-2 oncogene (B.rnes et al, 1992). Despite
associations between amplification/overexpression of this onco-
gene and poor prognosis in invasive breast tumours, these studies
showed much higher levels of overexpression in preinvasive
comedo DCIS than infiltrating breast carcinomas. This could be
explained if there existed a subgroup of invasive tumours that,
despite a lack of c-erbB-2 positivity, were still associated with
poor prognosis. DCIS cases showing staining for this oncoprotein
were also associated with a greater invasive potential, but it was
suggested that for those invasive cancers that did not show
staining, their high rate of proliferation and associated malignant
potential was possibly correlated with particular characteristics of
nuclear grade. Such cases were expected to have only a transient
progression through apreinvasive DCIS stage, which would prob-
ably not be observed as negative staining in DCIS. Hence, rela-
tively fewer DCIS cases than invasive tumours would be negative
for c-erbB-2 staining. Similarly, in this study, alterations to chro-
mosome 9p may be important in the progression to neoplasia of a
subgroup oftumours, although, in the absence of such alterations,
as in the invasive carcinomas studied, other features must be
considered.
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